Last reviewed · How we verify
FOLFIRI, target agent
At a glance
| Generic name | FOLFIRI, target agent |
|---|---|
| Sponsor | Joong Bae Ahn |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (EARLY_PHASE1)
- Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI (PHASE3)
- Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM (PHASE2)
- Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (PHASE2)
- Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis (PHASE2)
- SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases (PHASE3)
- Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (PHASE1)
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFIRI, target agent CI brief — competitive landscape report
- FOLFIRI, target agent updates RSS · CI watch RSS
- Joong Bae Ahn portfolio CI